Perrigo Company plc (PRGO)


NYSE - NYSE Real Time Price. Currency in USD
95.32-1.96 (-2.01%)
As of 11:23 AM EDT. Market open.
People also watch:
MYLENDPALXNREGNTEVA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open97.63
Prev Close97.28
Bid96.35 x 100
Ask96.38 x 200
Day's Range95.31 - 98.15
52wk Range82.50 - 167.92
1y Target EstN/A
Market Cap13.66B
P/E Ratio (ttm)-152.76
Beta0.75
Volume413,510
Avg Vol (3m)2,136,098
Dividend & Yield0.58 (0.60%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Kiplinger2 days ago

    7 Good Stocks That Are Due for a Turnaround

    Thinkstock If you had invested $100,000 five years ago in a low-cost fund that tracks Standard & Poor's 500-stock index, you'd be sitting pretty today. Over that period, the index has returned an annualized ...

  • PR Newswire2 days ago

    Perrigo Invests In Tarex® Patented Technology, As A Key Investment In The Fight Against Methamphetamine Drug Abuse

    TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the distribution rights of Zephrex-D® (pseudoephedrine HCI 30 mg).  Zephrex-D® was developed using the Tarex® technology and has been proven to be more than 98% effective at blocking one of the more common domestic methods of illegal meth production. This agreement is part of Perrigo's ongoing efforts in the fight against meth drug abuse. Perrigo's Executive Vice President & President, Consumer Healthcare - Americas, Jeff Needham commented that, "Across the country, illegal methamphetamine use continues to be a significant issue.

  • Market Realist8 days ago

    What Is the Upside Potential for Valeant?

    Share price estimates for Valeant Valeant Pharmaceuticals (VRX) operates in the specialty pharmaceutical industry. With controversies associated with its huge debt, price gouging, and the Philidor controversy, ...